Hot Stock in Foucs: Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

April 25, 2023 8:19 am3 commentsViews: 77

GlycoMimetics Inc(NASDAQ:GLYC) reported on Pfizer Inc. (NYSE:PFE) has dosed the first patient in the Phase 3 Trial of rivipansel for the treatment of vaso-occlusive crisis in patients hospitalized by means of sickle cell disease who are six years of age or older. The begin of the examination triggered the second milestone payment from Pfizer to GlycoMimetics totaling $20M. In May 2014, GlycoMimetics received a $15 million milestone payment from Pfizer. The Phase 3 trial is planning to enroll at least 350 individuals with sickle cell disease who are hospitalized for a vaso-occlusive crisis, and will evaluate the efficacy and safety of treatment with rivipansel. Shares of Pfizer Inc. (NYSE:PFE) opened at $34.41 with 6157.67 million outstanding shares and hit to its highest price of $34.59 during the day and finally closed at $34.50 by scoring 0.55%. In the whole session, it traded on volume of 18.45 Million shares, which turned higher than its average volume.

Eli Lilly and Company (NYSE:LLY) declared that The Lancet Oncology has released results of the Phase III REACH trial that evaluated Cyramza (ramucirumab) as a second-line treatment for populace by means of hepatocellular carcinoma or HCC, also known as liver cancer. While the REACH trial’s primary endpoint of overall survival favored the Cyramza arm, it was not statistically significant. However, encouraging single-agent Cyramza activity was observed, with meaningful improvements in key secondary endpoints as well as within certain patient subgroups. Eli Lilly and Company (NYSE:LLY) stock hit highest price at $83.75, beginning with a price of $83.75 to close at 82.67 by a decrease of -0.30% with a day range of $82.45-$83.75.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) and Progenics Pharmaceuticals, Inc. (PGNX) released that Valeant submitted a New Drug Application to the U.S. Food and Drug Administration for RELISTOR (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation or OIC in adult patients by means of chronic non-cancer pain. RELISTOR is a peripherally acting mu-opioid receptor antagonist specially designed to block the constipating effects of opioid pain medications in the gastrointestinal tract. On the other consideration, Valeant Pharmaceuticals International, Inc. (NYSE:VRX) begun last trade with a price of $234.15 and throughout the trading session climbed at $236.12. The day-trade ended with a gain of 0.15% to close at $233.25.


Leave a Reply

Show Buttons
Hide Buttons